Mechanism of Action of Botulinum Neurotoxin in the Lower Urinary Tract

Botulinum Toxin: Therapeutic Clinical Practice and Science

Volumn , Issue , 2009, Pages 231-240

  Chancellor, Michael B ^a   Somogyi, George T ^b   Smith, Christopher P ^b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77951008956     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-4928-9.00019-6     Document Type: Chapter

References (74)

1. Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005, 174:196-200.
2. Simpson LL The action of botulinal toxin. Rev Infect Dis 1979, 1:656-662.
3. Atiemo H, Wynes J, Chuo J, Nipkow L, Sklar GN, Chai TC Effect of botulinum toxin on detrusor overactivity induced by intravesical adenosine triphosphate and capsaicin in a rat model. Urology 2005, 65:622-626.
4. Holman ME, Spitzer NC Action of botulinum toxin on transmission from sympathetic nerves to the vas deferens. Br J Pharmacol 1973, 47:431-433.
5. Pasricha PJ, Ravich WJ, Kalloo AN Effects of intrasphincteric botulinum toxin on the lower esophageal sphincter in piglets. Gastroenterology 1993, 105:1045-1049.
6. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 1993, 113:400-404.
7. Rosales RL, Arimura K, Takenaga S, Osame M Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996, 19:488-496.
8. Modugno N, Priori A, Berardelli A, Vacca L, Mercuri B, Manfredi M Botulinum toxin restores presynaptic inhibition of group Ia afferents in patients with essential tremor. Muscle Nerve 1998, 21:1701-1705.
9. Giannantoni A, Di Stasi SM, Nardicchi V, Zucchi A, Macchioni L, Bini V, et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 2006, 175:2341-2344.
10. Borodic GE, Ferrante R Effects of repeated botulinum toxin injections on orbicularis oculi muscle. J Clin Neuroophthalmol 1992, 12:121-127.
11. Spencer RF, McNeer KW Botulinum toxin paralysis of adult monkey extraocular muscle. Structural alterations in orbital, singly innervated muscle fibers. Arch Ophthalmol 1987, 105:1703-1711.
12. Harris CP, Alderson K, Nebeker J, Holds JB, Anderson RL Histologic features of human orbicularis oculi treated with botulinum A toxin. Arch Ophthalmol 1991, 109:393-395.
13. Borodic GE, Mills L, Joseph M Botulinum A toxin for the treatment of adult-onset spasmodic torticollis. Plast Reconstr Surg 1991, 87:285-289.
14. Thesleff S, Molgo J, Tagerud S Trophic interrelations at the neuromuscular junction as revealed by the use of botulinal neurotoxins. J Physiol (Paris) 1990, 84:167-173.
15. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A 1999, 96:3200-3205.
16. Alderson K, Holds JB, Anderson RL Botulinum-induced alteration of nerve-muscle interactions in the human orbicularis oculi following treatment for blepharospasm. Neurology 1991, 41:1800-1805.
17. Juzans P, Comella JX, Molgo J, Faille L, Angaut-Petit D Nerve terminal sprouting in botulinum type-A treated mouse levator auris longus muscle. Neuromuscul Disord 1996, 6:177-185.
18. Angaut-Petit D, Molgo J, Comella JX, Faille L, Tabti N Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: morphological and electrophysiological features. Neuroscience 1990, 37:799-808.
19. Van Putten MJ, Padberg M, Tavy DL In vivo analysis of end-plate noise of human extensor digitorum brevis muscle after intramuscularly injected botulinum toxin type A. Muscle Nerve 2002, 26:784-790.
20. Chancellor MB, O'Leary M, Erickson J, Cannon TW, Chermansky C, Leng WW, et al. Successful use of bladder botulinum toxin injection to treat refractory overactive bladder [abstract DP50]. 98th Annual Meeting of the American Urological Association 2003, Chicago, IL, USA.
21. Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005, 174:984-989.
22. Smith CP, Nishiguchi J, O'Leary M, Yoshimura N, Chancellor MB Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 2005, 65:37-41.
23. Smith CP, Franks ME, McNeil BK, Ghosh R, de Groat WC, Chancellor MB Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 2003, 169:1896.
24. Somogyi GT, Tanowitz M, Zernova G, de Groat WC M1 muscarinic receptor-induced facilitation of ACh and noradrenaline release in the rat bladder is mediated by protein kinase C. J Physiol 1996, 496(Pt 1):245-254.
25. Chu FM, Dmochowski R Pathophysiology of overactive bladder. Am J Med 2006, 119(3 suppl 1):3-8.
26. Somogyi GT, Zernova GV, Yoshiyama M, Yamamoto T, de Groat WC Frequency dependence of muscarinic facilitation of transmitter release in urinary bladder strips from neurally intact or chronic spinal cord transected rats. Br J Pharmacol 1998, 125:241-246.
27. Apostolidis A, Dasgupta P, Fowler CJ Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006, 49:644-650.
28. MacKenzie I, Burnstock G, Dolly JO The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience 1982, 7:997-1006.
29. Kim HJ, Seo K, Yum KW, Oh YS, Yoon TG, Yoon SM Effects of botulinum toxin type A on the superior cervical ganglia in rabbits. Auton Neurosci 2002, 102:8.
30. Morris JL, Jobling P, Gibbins IL Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol Heart Circ Physiol 2001, 281:H2124.
31. Ishikawa H, Mitsui Y, Yoshitomi T, Mashimo K, Aoki S, Mukono K, et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Nippon Ganka Gakkai Zasshi 2001, 105:218.
32. Smith CP, Boone TB, de Groat WC, Chancellor MB, Somogyi GT Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res Bull 2003, 61:165.
33. O'Reilly BA, Kosaka AH, Knight GF, Chang TK, Ford AP, Rymer JM, et al. P2X receptors and their role in female idiopathic detrusor instability. J Urol 2002, 167:157-164.
34. Hawthorn MH, Chapple CR, Cock M, Chess-Williams R Urothelium-derived inhibitory factor(s) influence detrusor muscle contractility in vitro. Br J Pharmacol 2000, 129:416-419.
35. Wakabayashi Y, Kojima Y, Makiura Y, Tomoyoshi T, Maeda T Acetylcholinesterase positive axons in the mucosa of urinary bladder of adult cats: retrograde tracing and degeneration studies. Histol Histopathol 1995, 10:523-530.
36. Andersson KE, Yoshida M Antimuscarinics and the overactive detrusor-which is the main mechanism of action. Eur Urol 2003, 43:1-5.
37. Khera M, Somogyi GT, Kiss S, Boone TB, Smith CP Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 2004, 45:987-993.
38. Rapp DE, Turk KW, Bales GT, Cook SP Botulinum toxin type A inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 2006, 175(3 Pt 1):1138-1142.
39. Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 2004, 172(4 Pt 1):1529-1532.
40. Bayliss M, Wu C, Newgreen D, Mundy AR, Fry CH A quantitative study of atropine-resistant contractile responses in human detrusor smooth muscle, from stable, unstable and obstructed bladders. J Urol 1999, 162:1833-1839.
41. Sperlagh B, Vizi ES Is the neuronal ATP release from guinea-pig vas deferens subject to alpha 2-adrenoceptor-mediated modulation?. Neuroscience 1992, 51:203-209.
42. Todorov LD, Mihaylova-Todorova S, Craviso GL, Bjur RA, Westfall DP Evidence for the differential release of the cotransmitters ATP and noradrenaline from sympathetic nerves of the guinea-pig vas deferens. J Physiol 1996, 496(Pt 3):731-748.
43. Tong YC, Hung YC, Shinozuka K, Kunitomo M, Cheng JT Evidence of adenosine 5'-triphosphate release from nerve and P2x-purinoceptor mediated contraction during electrical stimulation of rat urinary bladder smooth muscle. J Urol 1997, 158:1973-1977.
44. Ferguson DR, Kennedy I, Burton TJ ATP is released from rabbit urinary bladder epithelial cells by hydrostatic pressure changes-a possible sensory mechanism?. J Physiol 1997, 505(Pt 2):503-511.
45. Birder LA, Nakamura Y, Kiss S, Nealen ML, Barrick S, Kanai AJ, et al. Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat Neurosci 2002, 5:856-860.
46. Ferguson DR Urothelial function. BJU Int 1999, 84:235-242.
47. Sun Y, Keay S, De Deyne PG, Chai TC Augmented stretch activated adenosine triphosphate release from bladder uroepithelial cells in patients with interstitial cystitis. J Urol 2001, 166:1951-1956.
48. Ford AP, Gever JR, Nunn PA, Zhong Y, Cefalu JS, Dillon MP, et al. Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Br J Pharmacol 2006, 147(Suppl 2):S132-S143.
49. Paukert M, Osteroth R, Geisler HS, Brandle U, Glowatzki E, Ruppersberg JP, et al. Inflammatory mediators potentiate ATP-gated channels through the P2X(3) subunit. J Biol Chem 2001, 276:21077-21082.
50. Cortright DN, Szallasi A Biochemical pharmacology of the vanilloid receptor TRPV1. An update 2004, 271:1814-1819.
51. Morenilla-Palao C, Planells-Cases R, Garcia-Sanz N, Ferrer-Montiel A Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 2004, 279:25665-25672.
52. Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005, 174:977-982.
53. Apostolidis A, Dasgupta P, Fowler CJ Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006, 49:644-650.
54. Basbaum AI, Jessell TM The perception of pain. Principles of Neural Science 2000, 472-491. McGraw Hill, New York. 4th. E.R. Kandel, J.H. Schwartz, T.M. Jessell (Eds.).
55. Aoki KR Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005, 26:785-793.
56. Zubrzycka M, Janecka A Substance P: transmitter of nociception (Minireview). Endocr Regul 2000, 34:195-201.
57. Steers WD, Tuttle JB Mechanisms of disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat Clin Pract Urol 2006, 3:101-110.
58. Giannantoni A, Di Stasi SM, Nardicchi V, Zucchi A, Macchioni L, Bini V, et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 2006, 175:2341-2344.
59. Relja M, Telarovic S Botulinum toxin type-A and pain responsiveness in cervical dystonia: A dose response study. Mov Disord 2005, 20:S10.
60. Foster KA The analgesic potential of clostridial neurotoxin derivatives. Expert Opin Investig Drugs 2004, 13:1437-1443.
61. Tarsy D, First ER Painful cervical dystonia: clinical features and response to treatment with botulinum toxin. Mov Disord 1999, 14:1043-1045.
62. Brin MF, Fahn S, Moskowitz C, Friedman A, Shale HM, Greene PE, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv Neurol 1988, 50:599-608.
63. Tsui JK, Fross RD, Calne S, Calne DB Local treatment of spasmodic torticollis with botulinum toxin. Can J Neurol Sci 1987, 14(3 suppl):533-535.
64. Haferkamp A, Schurch B, Reitz A, Krengel U, Grosse J, Kramer G, et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder. Eur Urol 2004, 46:784-791.
65. Comperat E, Reitz A, Delcourt A, Capron F, Denys P, Chartier-Kastler E Histologic features in the urinary bladder wall affected from neurogenic overactivity-a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 2006, 50:1058-1064.
66. Mejia NI, Vuong KD, Jankovic J Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 2005, 20:592-597.
67. Coletti Moja M, Dimanico U, Mongini T, Cavaciocchi V, Gerbino Promis PC, Grasso E Acute neuromuscular failure related to long-term botulinum toxin therapy. Eur Neurol 2004, 51:181-183.
68. Grosse J, Kramer G, Stohrer M Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005, 47:653-659.
69. Altaweel W, Jednack R, Bilodeau C, Corcos J Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele. J Urol 2006, 175(3 Pt 1):1102-1105.
70. Schulte-Baukloh H, Weiss C, Stolze T, Sturzebecher B, Knispel HH Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology 2005, 66:82-87.
71. Schulte-Baukloh H, Knispel HH, Stolze T, Weiss C, Michael T, Miller K Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology 2005, 66:865-870. discussion 870.
72. Kessler TM, Danuser H, Schumacher M, Studer UE, Burkhard FC Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity?. Neurourol Urodyn 2005, 24:231-236.
73. Kuo HC Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 2005, 66:94-98.
74. Meunier FA, Schiavo G, Molgo J Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol (Paris) 2002, 96:105-113.